Press Releases
Date Title and Summary View
Jun 8, 2016 DURHAM, N.C., June 08, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the comp...
May 12, 2016 - Entered into Equity Financing for Up to $60 million - - Phase 3 ADAPT trial of AGS-003 in Metastatic Renal Cell Carcinoma On Track for Upcoming Review by Independent Data Monitoring Committee - - Dr. Lee F. Allen joined as Chief Medical Office...
May 11, 2016 DURHAM, N.C., May 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the ...
May 5, 2016 DURHAM, N.C., May 05, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on the Arcelis® technology platform, today announced that the Company's first quarter 2016...
Apr 7, 2016 DURHAM, N.C., April 07, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the...
Mar 29, 2016 DURHAM, N.C., March 29, 2016 (GLOBE NEWSWIRE) -- In the release issued earlier today by Argos Therapeutics (Nasdaq:ARGS), please note that the "Selected Third Quarter 2015 Financial Results" header should be "Selected Fourth Quarter and Full-Year 2015 Financial Results." All other information in the press release remains the same.Media c...
Mar 29, 2016 - Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 in July 2015 —  - Independent Data Monitoring Committee (IDMC) Recommended Continuation of Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 Following Data Reviews in June and December 2015 - ...
Mar 23, 2016 DURHAM, N.C., March 23, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the initiation of an...
Mar 22, 2016 DURHAM, N.C., March 22, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, today announced that the Company's fourth quarter and full-year 2015...
Mar 22, 2016 DURHAM, N.C., March 22, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the company ...
FirstPrevious
2
... NextLast
Add to Briefcase = add release to Briefcase

Quick Links





Tweets